{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:07:53Z","timestamp":1783076873271,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Health Science and Technology Development Major Project of Nanjing","award":["ZDX21001"],"award-info":[{"award-number":["ZDX21001"]}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7212080"],"award-info":[{"award-number":["7212080"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-alcoholic fatty liver disease (NAFLD) is easily neglected in the non-obese population. TyG index (triglyceride glucose Index) and TG\/HDL-c (triglyceride to high-density lipoprotein cholesterol) are new indicators to evaluate insulin resistance (IR). Fibroscan is a non-invasive way to assess hepatic steatosis [by control attenuation parameters (CAP)] and fibrosis [by liver stiffness measurement (LSM)].The purpose of this study was to explore the correlation of TyG and its combination with obesity indicators [TyG-waist circumference (WC), TyG-body mass index (BMI)] and TG\/HDL-c with CAP and LSM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>One thousand seven hundred seventy-six adults (age\u2009\u2265\u200920\u00a0years, BMI\u2009&lt;\u200930\u00a0kg\/m2) in the National Health and Nutrition Examination Survey (NHANES) 2017\u20132018 were included. The correlations of CAP and LSM to the indexes were assessed by generalized linear models.. Receiver operating characteristic (ROC) curve was performed to evaluate the diagnostic capability of the indicators on NAFLD and liver stiffness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Survey-weighted percentage of NAFLD in non-obese was 38.6%. In the fully adjusted models, there were positive associations of TyG, TyG-BMI, TyG-WC and TG\/HDL-c to CAP, with the \u03b2s of 24.810, 0.704, 0.29 and 2.983 (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), respectively. There were positive associations of TyG, TyG-BMI, TyG-WC, and TG\/HDL-c to NAFLD, with ORs of 3.387, 1.03, 1.010 and 1.281 ((all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05)).The positive association was detected for TG\/HDL-c and TyG-WC and LSM with \u03b2s of 0.057 and 0.004(<jats:italic>p<\/jats:italic>\u2009=\u20090.021 and <jats:italic>p<\/jats:italic>\u2009=\u20090.003).TyG-WC were positively associated with liver stiffness with OR of 1.006(95%CI\u2009=\u20091.002, 1.012). Furthermore, the TyG-WC had the strongest diagnostic capability (ROC\u2009=\u20090.806; 95%CI: 0.785\u20130.826) on NAFLD in non-obese participants, with a specificity of 0.737 and sensitivity of 0.746.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In US non-obese population, the TyG, TyG-BMI, TyG-WC, and TG\/HDL-c are positively correlated with CAP and NAFLD. TyG-WC has clinical importance in identifying NAFLD in the non-obese population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-03007-8","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T09:02:51Z","timestamp":1698915771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults"],"prefix":"10.1186","volume":"23","author":[{"given":"Shuying","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangbin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangfeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"1","key":"3007_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"1","key":"3007_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"3007_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123\u201333.","journal-title":"Hepatology"},{"issue":"3","key":"3007_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.22365\/jpsych.2019.303.189","volume":"30","author":"A Agorastos","year":"2019","unstructured":"Agorastos A, Bozikas VP. Gut microbiome and adaptive immunity in schizophrenia. Psychiatriki. 2019;30(3):189\u201392.","journal-title":"Psychiatriki"},{"issue":"4","key":"3007_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cgh.2016.08.028","volume":"15","author":"D Kim","year":"2017","unstructured":"Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(4):474\u201385.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3007_CR6","doi-asserted-by":"publisher","first-page":"4678526","DOI":"10.1155\/2020\/4678526","volume":"2020","author":"A Sanchez-Garcia","year":"2020","unstructured":"Sanchez-Garcia A, et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review. Int J Endocrinol. 2020;2020:4678526.","journal-title":"Int J Endocrinol"},{"issue":"2","key":"3007_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","volume":"70","author":"RS Khan","year":"2019","unstructured":"Khan RS, et al. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711\u201324.","journal-title":"Hepatology"},{"issue":"3","key":"3007_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MOG.0000000000000621","volume":"36","author":"A Khalifa","year":"2020","unstructured":"Khalifa A, Rockey DC. The utility of liver biopsy in 2020. Curr Opin Gastroenterol. 2020;36(3):184\u201391.","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"3007_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","volume":"51","author":"NF Schwenzer","year":"2009","unstructured":"Schwenzer NF, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51(3):433\u201345.","journal-title":"J Hepatol"},{"issue":"6","key":"3007_CR10","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1053\/j.gastro.2008.02.077","volume":"134","author":"DM Torres","year":"2008","unstructured":"Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134(6):1682\u201398.","journal-title":"Gastroenterology"},{"issue":"1","key":"3007_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","volume":"19","author":"K Pu","year":"2019","unstructured":"Pu K, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51.","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"3007_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/diagnostics10110940","volume":"10","author":"S Oeda","year":"2020","unstructured":"Oeda S, et al. Diagnostic accuracy of fibroscan and factors affecting measurements. Diagnostics. 2020;10(11):940.","journal-title":"Diagnostics"},{"issue":"5","key":"3007_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE Mozes","year":"2022","unstructured":"Mozes FE, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006\u201319.","journal-title":"Gut"},{"issue":"2","key":"3007_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","volume":"44","author":"R Lomonaco","year":"2021","unstructured":"Lomonaco R, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care. 2021;44(2):399\u2013406.","journal-title":"Diabetes Care"},{"issue":"5","key":"3007_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022\u201330.","journal-title":"J Hepatol"},{"issue":"8","key":"3007_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3007_CR17","doi-asserted-by":"publisher","first-page":"e0252164","DOI":"10.1371\/journal.pone.0252164","volume":"16","author":"X Zhang","year":"2021","unstructured":"Zhang X, et al. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: results from NHANES 2017\u20132018. PLoS One. 2021;16(6):e0252164.","journal-title":"PLoS One"},{"issue":"6","key":"3007_CR18","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/jgh.15353","volume":"36","author":"M Ahadi","year":"2021","unstructured":"Ahadi M, et al. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2021;36(6):1497\u2013507.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"3007_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1136\/flgastro-2018-101119","volume":"11","author":"M Phipps","year":"2020","unstructured":"Phipps M, Wattacheril J. Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals. Frontline Gastroenterol. 2020;11(6):478\u201383.","journal-title":"Frontline Gastroenterol"},{"issue":"6","key":"3007_CR20","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","volume":"14","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875\u201387.","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"3007_CR21","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343\u201351.","journal-title":"J Clin Invest"},{"key":"3007_CR22","doi-asserted-by":"publisher","first-page":"172715","DOI":"10.1016\/j.ejphar.2019.172715","volume":"864","author":"X Yu","year":"2019","unstructured":"Yu X, et al. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy. Eur J Pharmacol. 2019;864:172715.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"3007_CR23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1172\/JCI21047","volume":"113","author":"S Nielsen","year":"2004","unstructured":"Nielsen S, et al. Splanchnic lipolysis in human obesity. J Clin Invest. 2004;113(11):1582\u20138.","journal-title":"J Clin Invest"},{"issue":"2","key":"3007_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/apt.14112","volume":"46","author":"S Sookoian","year":"2017","unstructured":"Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46(2):85\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"3007_CR25","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461\u20135.","journal-title":"Nat Genet"},{"issue":"5","key":"3007_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina RM, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150(5):1219-1230.e6.","journal-title":"Gastroenterology"},{"issue":"1","key":"3007_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-022-01511-x","volume":"21","author":"L Tao","year":"2022","unstructured":"Tao L, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3007_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mend\u00eda","year":"2008","unstructured":"Simental-Mend\u00eda LE, Rodr\u00edguez-Mor\u00e1n M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299\u2013304.","journal-title":"Metab Syndr Relat Disord"},{"issue":"5","key":"3007_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2174\/1871530319666190121123535","volume":"19","author":"EG Behiry","year":"2019","unstructured":"Behiry EG, et al. Evaluation of TG-HDL ratio instead of HOMA ratio as insulin resistance marker in overweight and children with obesity. Endocr Metab Immune Disord Drug Targets. 2019;19(5):676\u201382.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"3007_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8565943","volume":"2021","author":"X Ye","year":"2021","unstructured":"Ye X, et al. Pentraxin 3 and the TyG Index as Two Novel Markers to Diagnose NAFLD in Children. Dis Markers. 2021;2021:1\u20137.","journal-title":"Dis Markers"},{"key":"3007_CR31","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.clnesp.2021.04.025","volume":"44","author":"H Tutunchi","year":"2021","unstructured":"Tutunchi H, et al. Triglyceride glucose (TyG) index and the progression of liver fibrosis: a cross-sectional study. Clin Nutr ESPEN. 2021;44:483\u20137.","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"3007_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12944-017-0409-6","volume":"16","author":"S Zhang","year":"2017","unstructured":"Zhang S, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):15.","journal-title":"Lipids Health Dis"},{"issue":"3","key":"3007_CR33","first-page":"261","volume":"68","author":"R Catanzaro","year":"2022","unstructured":"Catanzaro R, et al. Triglycerides to high-density lipoprotein cholesterol ratio for diagnosing nonalcoholic fatty liver disease. Minerva Gastroenterol (Torino). 2022;68(3):261\u20138.","journal-title":"Minerva Gastroenterol (Torino)"},{"issue":"2","key":"3007_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11901-016-0302-1","volume":"15","author":"J Wattacheril","year":"2016","unstructured":"Wattacheril J, Sanyal AJ. Lean NAFLD: an underrecognized outlier. Curr Hepatol Rep. 2016;15(2):134\u20139.","journal-title":"Curr Hepatol Rep"},{"issue":"1","key":"3007_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cgh.2015.07.024","volume":"14","author":"D Kim","year":"2016","unstructured":"Kim D, et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):132-8.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"38","key":"3007_CR36","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","volume":"24","author":"M Papatheodoridi","year":"2018","unstructured":"Papatheodoridi M, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): current concepts. Curr Pharm Des. 2018;24(38):4574\u201386.","journal-title":"Curr Pharm Des"},{"issue":"40","key":"3007_CR37","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3748\/wjg.v25.i40.6053","volume":"25","author":"G Ferraioli","year":"2019","unstructured":"Ferraioli G, Soares ML. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019;25(40):6053\u201362.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3007_CR38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/hep.31121","volume":"72","author":"R Loomba","year":"2020","unstructured":"Loomba R, et al. Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH. Hepatology. 2020;72(4):1219\u201329.","journal-title":"Hepatology"},{"issue":"1","key":"3007_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12944-020-01393-6","volume":"19","author":"W Guo","year":"2020","unstructured":"Guo W, et al. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. Lipids Health Dis. 2020;19(1):218.","journal-title":"Lipids Health Dis"},{"issue":"3","key":"3007_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/met.2020.0109","volume":"19","author":"ME Khamseh","year":"2021","unstructured":"Khamseh ME, et al. Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight\/obesity. Metab Syndr Relat Disord. 2021;19(3):167\u201373.","journal-title":"Metab Syndr Relat Disord"},{"issue":"4","key":"3007_CR41","doi-asserted-by":"publisher","first-page":"101345","DOI":"10.1016\/j.diabet.2022.101345","volume":"48","author":"B Riviere","year":"2022","unstructured":"Riviere B, et al. The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. Diabetes Metab. 2022;48(4):101345.","journal-title":"Diabetes Metab"},{"issue":"3","key":"3007_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/ajg.2016.14","volume":"111","author":"EB Tapper","year":"2016","unstructured":"Tapper EB, et al. Erratum: cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration-controlled transient elastography. Am J Gastroenterol. 2016;111(3):446\u2013446.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03007-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03007-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03007-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T09:05:12Z","timestamp":1698915912000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03007-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3007"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03007-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving research study participants were approved by the National Center for Health Statistics Research Ethics Review Board. Written informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"376"}}